The prognosis of patients with CLL has been traditionally assessed by using clinical stages. Clinical stages, however, are a mere reflection of the biological diversity of CLL. In this regard, we and others have recently shown that ZAP-70 expression separates CLL into two clinical forms with different outcome. The aim of this study was to analyze the distribution of age, gender, and different prognostic parameters according to ZAP-70 expression in 222 pts with CLL (median age, 62 yrs; female/male: 89/133). ZAP-70 was determined by flow cytometry, a high expression being defined as >20% ZAP-70 positive CLL cells. Median follow-up of the series was 7.1 years. Clinical stages at diagnosis were: Binet stage A, 187 pts; B, 21 pts; and C, 14 pts. Rai Stage 0, 123 pts; I, 53 pts; II, 28 pts; III, 7 pts; and IV, 11 pts. Overall median survival was 13 years. Parameters associated with a high ZAP-70 expression were lymphocyte doubling time >12 mos., atypical morphology, bone marrow infiltration > 60%, increased serum LDH and timidin kinase, CD38 expression >20%, del(13q14), unmutated status of IgVH, and development of Richer syndrome. Interestingly, ZAP-70 expression distribution correlated with Rai’s stage (0 vs. 1 to 4). Also, CD38 expression was able to separate two subpopulations with different survival among CLL cases with low ZAP-70 expression (median survival 18 yrs vs. 13 yrs), but not in pts. with ZAP-70>20%. About 50% of pts in Binet A progressed during the follow-up. Median time to progression for patients with high ZAP-70 expression was 3.3 years whereas it was not reached for patients with low ZAP-70 expression. Median survival of pts with low ZAP-70 expression was 16.3 years, whereas it was of 8.5 years in those with high ZAP-70 expression. In conclusion, ZAP-70 expression identifies a subgroup of patients with CLL with unfavorable prognostic factors related to the proliferation and progression of the disease.

Prognostic Parameters according to ZAP-70 expression

VariableZAP-70 >20%ZAP-70 < 20%p=
Median age 60 yrs 63 yrs  
Gender (female) 39% 41%  
LDT < 12 mos 42% 23% 0.009 
Atypical morphology 54% 12% 0.000 
BM infiltration >60% 50% 33% 0.03 
Increased LDH 13% 4% 0.028 
Increased TK 66% 28% 0.000 
CD38 > 20% 67% 32% 0.000 
Del(13q14) 38% 55% 0.027 
Unmutated IgVH 88% 11% 0.000 
Richter Syndrome 8% 2% 0.039 
Rai Stage > 0 53% 37% 0.039 
TTP (Binet A) 3.3 yrs NR 0.000 
Median Survival 16.3 yrs 8.5 yrs 0.000 
VariableZAP-70 >20%ZAP-70 < 20%p=
Median age 60 yrs 63 yrs  
Gender (female) 39% 41%  
LDT < 12 mos 42% 23% 0.009 
Atypical morphology 54% 12% 0.000 
BM infiltration >60% 50% 33% 0.03 
Increased LDH 13% 4% 0.028 
Increased TK 66% 28% 0.000 
CD38 > 20% 67% 32% 0.000 
Del(13q14) 38% 55% 0.027 
Unmutated IgVH 88% 11% 0.000 
Richter Syndrome 8% 2% 0.039 
Rai Stage > 0 53% 37% 0.039 
TTP (Binet A) 3.3 yrs NR 0.000 
Median Survival 16.3 yrs 8.5 yrs 0.000 
View Large

Topics:
chronic b-cell leukemias, chronic lymphocytic leukemia, zap-70 kinase, brachial plexus neuritis, atypical, follow-up, flow cytometry, lactate dehydrogenase test, serum, phosphotransferases, prognostic factors

Author notes

Corresponding author

2005, The American Society of Hematology
2004
Sign in via your Institution